Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Auner, V; Kriegshäuser, G; Tong, D; Horvat, R; Reinthaller, A; Mustea, A; Zeillinger, R.
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
BMC Cancer. 2009; 9(1): 111-111.
Doi: 10.1186/1471-2407-9-111
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Kriegshäuser Gernot
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Mutations in the KRAS gene are one of the most frequent genetic abnormalities in ovarian carcinoma. They are of renewed interest as new epidermal growth factor receptor (EGFR)-targeted therapies are being investigated for use in ovarian carcinoma. As KRAS mutations are associated with poor response and resistance to EGFR-targeting drugs, this study was conducted to obtain more information on the spectrum of KRAS mutations in ovarian carcinoma. The presence of KRAS mutations in codon 12 and 13 was analyzed in frozen and formalin-fixed paraffin-embedded (FFPE) tissue with a low density biochip platform. 381 malignant (29 borderline malignancy, 270 primary carcinomas, and 82 recurrent carcinomas) and 22 benign tissue samples from a total of 394 patients were examined. KRAS mutational status of each sample was correlated with dignity, FIGO stage, grade, histology, and survival. KRAS mutations were found in 60 (15%) samples with 58 samples deriving from malignant tissue and 2 samples deriving from benign tissue. In 55 (92%) samples codon 12 was found to be mutated. Frozen and FFPE samples concurred with respect to KRAS mutation status. KRAS mutation is a common event in ovarian cancer primarily in carcinomas of lower grade, lower FIGO stage, and mucinous histotype. The KRAS mutational status is no prognostic factor for patients treated with standard therapy. However, in line with experience from colorectal cancer and non-small-cell-lung cancer (NSCLC), it may be important for prediction of response to EGFR-targeted therapies.
- Find related publications in this database (using NLM MeSH Indexing)
- Codon - genetics
- DNA Mutational Analysis - instrumentation DNA Mutational Analysis - methods DNA Mutational Analysis - statistics & numerical data
- Female -
- Gene Frequency -
- Humans -
- Mutation -
- Mutation, Missense -
- Ovarian Neoplasms - diagnosis Ovarian Neoplasms - genetics
- Ovary - metabolism Ovary - pathology
- Proportional Hazards Models -
- Proto-Oncogene Proteins - genetics
- Reproducibility of Results -
- Sensitivity and Specificity -
- Survival Analysis -
- ras Proteins - genetics